Intra-Articular Dexmedetomidine: A Treatment for Chronic Knee Pain
ConditionChronic Knee Pain
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-75
SponsorTanta University
About this trial
Chronic knee osteoarthritis (KOA) is a painful condition with limited treatment options. Non-pharmacological approaches often fall short, leading to decreased quality of life. Ozone therapy, a simple and affordable treatment, has shown promise for pain relief. Dexmedetomidine (DEX), a sedative and analgesic, has been used successfully as an adjuvant to anesthesia and local anesthetics. Given its potential for pain management, exploring DEX as a treatment for KOA could offer a new and promising approach.
Eligibility criteria
Qualifiers
Patients were not assigned for surgical intervention;
Patients were free of
Disqualifiers
Patients were assigned for surgical intervention;
Patients who had uncontrolled hypertension and/or diabetes mellitus;
Patients who had uncompensated cardiac, renal, or hepatic diseases;
Patients with coagulopathy, spinal deformity, allergy, or contraindication for the used drugs;
Trial design
Treatments tested in this trial
- Triamcinolone Acetonide
- Bupivacaine Hydrochloride
- Dexmedetomidine
Treatment groups
70 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov